when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

LILLY · news · pharmadog

← back to LILLY

News mentioning LILLY

793 stories

Sep 14, 26Axoltis misses the mark in phase 2 ALS study, but will persevere with the synthetic peptidefiercebiotech

Sep 14, 26Corbus posts phase 1 obesity data for drug mechanism that defeated Novo, Sanofifiercebiotech

Sep 14, 26STAT+: What’s in a name? Novo looks to a rebrandstat

Sep 14, 26No more Nordisk as Novo goes it alone amid rebranding pushfiercebiotech

Sep 14, 26Cellectis cans allogeneic CAR-Ts to hop aboard in vivo bandwagonfiercebiotech

Sep 14, 26Psychedelic therapies ride wave of public favor into FDA hearingbiospace

Sep 11, 26This week in charts: RA’s insatiable appetite, Novartis’ big slide and a reverse merger spreebiopharma dive

Sep 11, 26Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra usebiopharma dive

Sep 11, 26Frazier adds $1.1B+ to small and mid-sized biotech fundbiospace

Sep 11, 26Novartis drags peers down with triple asset stumblebiospace

Sep 11, 26Novartis drags peers down with triple asset failurebiospace

Sep 11, 26Novartis’ board faces investor scrutiny after M&A misfires and R&D flopsbiospace

Sep 10, 26Why two promising heart drugs flopped and what’s nextstat

Sep 10, 26Encoded raises $275M series F for Dravet syndrome gene therapybiospace

Sep 10, 2611 companies hiring in California nowbiospace

Sep 9, 26Kura spins diabetes work into a Lilly-backed biotech startupbiopharma dive

Sep 9, 26FDA gains ‘continuity’ as Mikhail, Davis named permanent CBER, CDER leadersbiopharma dive

Sep 9, 26Webinar: The Massive Scale of GLP-1s: Evolving Health, Healthcare and Marketsbiospace

Sep 9, 26Sandoz plans ‘vast and vertically integrated’ supply chain to support 100-biosimilar visionbiospace

Sep 9, 26Kura Oncology spins out diabetes pipeline with $50M and Lilly's helpendpoints

Sep 9, 26STAT+: Leukemia drug data suggested a different way to treat diabetes. A new biotech will test that ideastat

Sep 9, 26Caspian launches with $50M, Lilly support to advance disease-modifying diabetes betbiospace

Sep 9, 26Luma locks down 15-year, $410M fund for life science investmentsfiercebiotech

Sep 9, 26Kura creates Lilly-backed spinout armed with $50M to advance next-gen diabetes therapyfiercebiotech

Sep 9, 26Beyond China: Five other overseas destinations for biopharma dollarsbiospace

Sep 9, 26Steady stream of crossover rounds stock biotech's IPO pipelinebiospace

Sep 8, 26Moonwalk reloads with $70M and new RNAi prospects for obesitybiopharma dive

Sep 8, 26Schrödinger births new immunology and inflammation biotech, Tectora Therapeuticsfiercebiotech

Sep 8, 26Structure’s obesity portfolio impresses on GLP-1 and amylin fronts in dual data dropbiospace

Sep 8, 26AstraZeneca’s SERD pill overcomes adcomm defeat to win FDA nod in breast cancerbiospace

← prevpage 10 of 27next →